UK-based biotech Silence Therapeutics has appointed Dr Michael Khan as the company’s chief medical adviser.
Dr Khan is an associate professor of medicine at the University of Warwick and a consultant physician at University Hospitals.
In his role as adviser, he will help Silence develop translational clinical research involving its siRNA-based therapeutics for the treatment of orphan diseases, and those conditions with current unmet medical need.
“I believe that Silence Therapeutics core technologies are uniquely positioned to fulfil these needs,” said Dr Khan.
Dr Khan’s previous roles include head of molecular medicine at Warwick University, where he helped develop various projects in cell and molecular biology.
His work has covered cancer and diabetes, and he has written several books on the subjects. He also teaches postgraduates and undergraduates in medicine and biological sciences in these areas.
In addition, Dr Khan is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART-UK and Diabetes UK.
“Michael’s medical, clinical and regulatory experience will be invaluable as we look to commercialise our prospects,” said Klaus Giese, chief scientific officer of Silence.